Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $8.2 million.

  • Ani Pharmaceuticals' Change in Inventory rose 2830.19% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 5888.49%. This contributed to the annual value of $21.3 million for FY2024, which is 26444.1% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Change in Inventory stood at $8.2 million for Q3 2025, which was up 2830.19% from $908000.0 recorded in Q2 2025.
  • Ani Pharmaceuticals' Change in Inventory's 5-year high stood at $11.6 million during Q2 2024, with a 5-year trough of -$5.9 million in Q3 2021.
  • In the last 5 years, Ani Pharmaceuticals' Change in Inventory had a median value of $2.3 million in 2023 and averaged $3.0 million.
  • In the last 5 years, Ani Pharmaceuticals' Change in Inventory plummeted by 43784.53% in 2021 and then soared by 163557.55% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Change in Inventory stood at $5.5 million in 2021, then skyrocketed by 70.52% to $9.5 million in 2022, then tumbled by 51.33% to $4.6 million in 2023, then crashed by 85.34% to $675000.0 in 2024, then skyrocketed by 1108.89% to $8.2 million in 2025.
  • Its Change in Inventory was $8.2 million in Q3 2025, compared to $908000.0 in Q2 2025 and $625000.0 in Q1 2025.